PeptidePedia The community reference

Contributions of SemaglutideSasha

User contributions·50 logged edits·page 1 of 1

Contributions by SemaglutideSasha, newest first. This list covers edits recorded in the site's change log; the editor's lifetime total of 18,406 edits includes activity predating the current log.

  1. 18:00, 26 Jul 2026 (diff | hist) Asymchem Laboratories 16,080 +1,280 add the incorporation year, attributed to the registry record
  2. 15:29, 17 Jul 2026 (diff | hist) Chain of custody 5,157 ±0 add the chain-of-custody point to §Limitations
  3. 10:12, 4 Jul 2026 (diff | hist) Shanghai ERP Biotechnology 14,637 ±0 add the minimum order quantity for custom synthesis
  4. 00:13, 28 Jun 2026 (diff | hist) GenScript Peptides 17,833 ±0 attribute the capability claim to the organisation's own material
  5. 09:40, 11 May 2026 (diff | hist) Talk:SUSTAIN trial programme 537 +151 /* Dose confusion with STEP */ new section
  6. 02:54, 30 Mar 2026 (diff | hist) Fmoc chemistry 4,618 ±0 correct the eutectic temperature — source gives a range
  7. 01:53, 10 Mar 2026 (diff | hist) Global access disparity 4,391 ±0 add the equity point with the study that measured it
  8. 20:42, 1 Mar 2026 (diff | hist) Proglucagon 6,709 ±0 move the trial material out of §Physiology into the compound articles
  9. 23:04, 26 Feb 2026 (diff | hist) Timeline of incretin therapeutics 4,460 ±0 m expand §Second generation and beyond
  10. 04:06, 21 Feb 2026 (diff | hist) Contract development and manufacturing organisation 5,011 ±0 m sentence case in headings per PP:MOS
  11. 17:25, 8 Feb 2026 (diff | hist) ChinaPeptides 14,979 ±0 add the see-also to the certificate-of-analysis article
  12. 08:05, 13 Jan 2026 (diff | hist) Talk:Semaglutide 822 +102 /* Weight-loss figure in the lead */ reply
  13. 09:40, 12 Jan 2026 (diff | hist) Talk:Semaglutide 400 +214 /* Weight-loss figure in the lead */ new section
  14. 04:46, 10 Jan 2026 (diff | hist) PolyPeptide Group (Hangzhou) 14,476 +61 m expand §Distribution and dispatch
  15. 13:35, 28 Dec 2025 (diff | hist) Karl Fischer titration 9,318 ±0 m expand §Interferences
  16. 22:39, 14 Dec 2025 (diff | hist) Triple agonist 4,269 ±0 m attribute the potency comparison to the head-to-head trial rather than to two separate ones
  17. 23:04, 4 Dec 2025 (diff | hist) Oral semaglutide 4,582 ±0 expand §Clinical position
  18. 01:16, 17 Nov 2025 (diff | hist) Solid-phase peptide synthesis 5,359 ±0 expand §Scale and its limits
  19. 21:00, 17 Oct 2025 (diff | hist) Customs seizure 4,785 +269 m add the cross-link to the legal-status-by-jurisdiction list
  20. 09:23, 14 Oct 2025 (diff | hist) AmbioPharm 3,408 +747 expand §External links
  21. 10:56, 8 Oct 2025 (diff | hist) Peptide content 8,404 ±0 m add the peptide-content point: area percent alone cannot give a mass
  22. 10:57, 6 Oct 2025 (diff | hist) Flourishglobal Peptide Biotech 11,943 +1,239 expand §Ordering and availability
  23. 01:49, 7 Sep 2025 (diff | hist) GLP-1 receptor agonist 11,148 ±0 rm duplicated pharmacokinetics — the same figures appear in the infobox
  24. 16:00, 20 Aug 2025 (diff | hist) Retatrutide 7,261 ±0 state the substitution in one-letter code as well, per PP:MOS
  25. 18:12, 4 Jul 2025 (diff | hist) Liraglutide 5,815 +547 split §Pharmacology into receptor binding and downstream signalling
  26. 14:26, 23 Jun 2025 (diff | hist) Multi-dose vial 16,561 +721 m state the assumption that the whole vial is reconstituted at once
  27. 18:01, 21 May 2025 (diff | hist) Liraglutide 5,268 ±0 add the structural figure and caption it properly
  28. 05:08, 11 May 2025 (diff | hist) Analytical method validation 5,074 +21 rm the claim that the method is stability-indicating without a forced-degradation study
  29. 17:50, 29 Apr 2025 (diff | hist) SELECT trial 4,206 ±0 ce per PP:MOS
  30. 06:56, 23 Apr 2025 (diff | hist) Lixisenatide 3,215 ±0 m fix the anchor on an internal link
  31. 21:20, 8 Apr 2025 (diff | hist) Survodutide 4,470 ±0 m add the year of first marketing authorisation, with the regulator named
  32. 00:26, 22 Mar 2025 (diff | hist) Semaglutide 8,079 ±0 m expand §Material sold outside licensed supply
  33. 01:28, 16 Mar 2025 (diff | hist) Retatrutide 5,700 ±0 m expand §Material sold as retatrutide
  34. 18:24, 24 Jan 2025 (diff | hist) Cold chain 17,977 +307 m fix a dangling clause
  35. 12:47, 25 Dec 2024 (diff | hist) CagriSema 2,915 +54 ce
  36. 12:23, 18 Dec 2024 (diff | hist) Retatrutide 4,597 +18 m de-orphan
  37. 18:56, 15 Dec 2024 (diff | hist) Oral semaglutide 3,213 ±0 m give the isoelectric point with the method it was determined by
  38. 10:34, 5 Dec 2024 (diff | hist) Bacterial endotoxin test 3,947 +1,018 give the limit of quantitation with the signal-to-noise ratio it assumes
  39. 10:24, 22 Nov 2024 (diff | hist) Orforglipron 1,574 ±0 m British spelling per PP:MOS
  40. 09:00, 20 Nov 2024 (diff | hist) Orforglipron 1,574 +1,574 N new article: compound, expansion welcome
  41. 11:12, 23 Oct 2024 (diff | hist) STEP trial programme 3,324 ±0 m state the non-inferiority margin, since the design was non-inferiority
  42. 07:46, 30 Sep 2024 (diff | hist) Amylin 1,974 ±0 split §Pharmacology into receptor binding and downstream signalling
  43. 14:43, 12 Sep 2024 (diff | hist) ISO 9001 1,587 ±0 m expand §What it implies about material
  44. 11:42, 12 Sep 2024 (diff | hist) Glucagon-like peptide-1 5,965 +138 rm the sentence implying the hormone is a drug
  45. 17:56, 7 Sep 2024 (diff | hist) Glucagon 3,652 +211 m add the receptor targets to the lead sentence
  46. 13:29, 6 Sep 2024 (diff | hist) Cagrilintide 1,887 ±0 m the lead claimed weekly dosing for a compound dosed daily; corrected
  47. 01:12, 16 Aug 2024 (diff | hist) Liraglutide 2,493 +1,051 the storage condition applies to the unopened pen; say so
  48. 08:45, 3 Aug 2024 (diff | hist) Reference standard 1,997 ±0 state the titration endpoint and the reagent factor
  49. 19:37, 31 Jul 2024 (diff | hist) Solid-phase peptide synthesis 2,254 +361 rm the vendor-specific packaging detail; not general enough for the article
  50. 08:15, 29 Jun 2024 (diff | hist) Semaglutide 2,607 +30 add see also to the amylin analogue